Pipette tips and pipettes — an infallible system?
ISO 8655:2002 recommends using pipettes and tips that are sourced from the same manufacturer.
In research involving pipetting, it has, on occasion, often been the case that experimental results were not easily reproducible, even though all variables within the experimental procedure have undergone a thorough review. So in these instances, can it be said that all sources of error have truly been accounted for?
In many cases the assumption is made that the pipetting system, consisting of pipette and pipette tip, is not a source of error as long as the tip fits the pipette. However, even if this is the case, it does not guarantee that the pipetting result will be accurate. Therefore, with good reason, the international standard ISO 8655:2002 recommends using pipettes and tips that are sourced from the same manufacturer.
Only under these conditions can the client be sure that each batch of manufactured pipette tips represents exactly the calibration result described in ISO 8655:2002. However, this is not the case for a non-system supplier; a non-system supplier does not have any system specifications to which they must refer. Hence, the user is forced to perform calibrations and, if necessary, make adjustments to the pipette with the foreign tips — every time tips of a new lot number are used.
The results of a large-scale study, in which an array of factors were identified as having the potential to negatively influence pipetting results, can be found in Application Note 354 “The Tip of the Iceberg — how tips influence results” at www.eppendorf.com/eptips
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.